@prefix : .
@prefix dc: .
@prefix fhir_link: .
@prefix ncit: .
@prefix rdf: .
@prefix rdfs: .
@prefix sso: .
@prefix whocv: .
@prefix xml: .
@prefix xsd: .
fhir_link: ;
dc:abstract "Current human papillomavirus (HPV) major capsid protein L1 virus-like particles (VLPs)-based vaccines in clinic induce strong HPV type-specific neutralizing antibody responses. To develop pan-HPV vaccines, here, we show that the fusion protein E3R4 consisting of three repeats of HPV16 L2 aa 17–36 epitope (E3) and a modified human IgG1 Fc scaffold (R4) induces cross-neutralizing antibodies and protective immunity against divergent HPV types. E3R4 was expressed as a secreted protein in baculovirus expression system and could be simply purified by one step Protein A affinity chromatography with the purity above 90%. Vaccination of E3R4 formulated with Freunds adjuvant not only induced cross-neutralizing antibodies against HPV pseudovirus types 16, 18, 45, 52, 58, 6, 11 and 5 in mice, but also protected mice against vaginal challenges with HPV pseudovirus types 16, 45, 52, 58, 11 and 5 for at least eleven months after the first immunization. Moreover, vaccination of E3R4 formulated with FDA approved adjuvant alum plus monophosphoryl lipid A also induced cross-neutralizing antibodies against HPV types 16, 18 and 6 in rabbits. Thus, our results demonstrate that delivery of L2 antigen as a modified Fc-fusion protein may facilitate pan-HPV vaccine development." ;
dc:creator "['Chen, Xue', 'Liu, Hongyang', 'Zhang, Ting', 'Liu, Yanchun', 'Xie, Xixiu', 'Wang, Zhirong', 'Xu, Xuemei']" ;
dc:identifier ,
,
;
dc:issued "2014-01-01"^^xsd:date ;
dc:license "CC BY" ;
dc:title "A Vaccine of L2 Epitope Repeats Fused with a Modified IgG1 Fc Induced Cross-Neutralizing Antibodies and Protective Immunity against Divergent Human Papillomavirus Types" ;
sso:has_full_text "True" ;
sso:journal "PLoS One" ;
sso:sha "ecea1d9607209bfcf32da251f53136e7f5c12f3e" ;
sso:source_x "PMC" .